BillionToOne reported that Q1 2026 revenue rose 84% year over year to $108.4 million, driven by growth in its prenatal testing business, and said it expects the Unity Confirm test to expand differentiation in high-risk follow-up. The company attributed the quarter’s prenatal growth to rising test volumes and said it expects further momentum from confirmatory testing. Unity Confirm is a circulating fetal cell-based, non-invasive assay designed to confirm high-risk screening results without invasive procedures such as CVS or amniocentesis. Management said less than 1% of patients screened positive are expected to require follow-up, but that Unity Confirm should increase utilization of the underlying Unity Aneuploidy screening offering. BillionToOne also said it is enrolling patients in a prospective clinical trial evaluating Unity Confirm against invasive testing, with expected readout timing of up to a few years.